Resource Summary Report

Generated by NIF on Sep 21, 2026

MDA-MB-468

RRID:CVCL_0419
Type: Cell Line

Proper Citation

RRID:CVCL_0419

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0419

Proper Citation: RRID:CVCL_0419

Description: Cell line MDA-MB-468 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast adenocarcinoma

Defining Citation: PMID:730202, PMID:1961733, PMID:3518877, PMID:9671407, PMID:10969801, PMID:11414198, PMID:12353263, PMID:12800145, PMID:15153330, PMID:15677628, PMID:16397213, PMID:16541312, PMID:17157791, PMID:18262045, PMID:18516279, PMID:19582160, PMID:19593635, PMID:20070913, PMID:20164919, PMID:21778573, PMID:22384151, PMID:22460905, PMID:22585861, PMID:22628656, PMID:23151021, PMID:23601657, PMID:23856246, PMID:24094812, PMID:24162158, PMID:24176112, PMID:24279929, PMID:25485619, PMID:25699542, PMID:25877200, PMID:25892236, PMID:25960936, PMID:26589293, PMID:27377824, PMID:27397505, PMID:27807467, PMID:28196595, PMID:28287265, PMID:28889351, PMID:29273624, PMID:30613774, PMID:30787054, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31978347, PMID:32576280, PMID:34703030, PMID:35839778, PMID:38861359, PMID:40300663

Comments: Population: African American., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: EGFR genetic alteration cell panel (ATCC TCP-1027)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MDA-MB-468

Synonyms: MDA-MB 468, MDA-MB468, MDAMB468, MDA-468, MDA468, MB468, MD Anderson-Metastatic Breast-468

Cross References: BTO:BTO_0001570, CLO:CLO_0007641, EFO:EFO_0001216, MCCL:MCC:0000316, CLDB:cl4973, AddexBio:C0006003/4673, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-6647, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:HTB-132, BCRJ:0166, BioGRID_ORCS_Cell_line:551, BioSample:SAMN03473056, BioSample:SAMN05292454, BioSample:SAMN10988340, cancercelllines:CVCL_0419, CCRID:1101HUM-PUMC000249, CCRID:3101HUMTCHu136, Cell_Model_Passport:SIDM00628, ChEMBL-Cells:CHEMBL3308424, ChEMBL-Targets:CHEMBL614335, CLS:300279, Cosmic:809241, Cosmic:850823, Cosmic:871149, Cosmic:877448, Cosmic:897427, Cosmic:904384, Cosmic:908123, Cosmic:923061, Cosmic:934530, Cosmic:949192, Cosmic:991327, Cosmic:997921, Cosmic:1000125, Cosmic:1010920, Cosmic:1017167, Cosmic:1018467, Cosmic:1044224, Cosmic:1046929, Cosmic:1047691, Cosmic:1136363, Cosmic:1152526, Cosmic:1176635, Cosmic:1287918, Cosmic:1289402, Cosmic:1305384, Cosmic:1309004, Cosmic:1477427, Cosmic:1523775, Cosmic:1524344, Cosmic:1571795, Cosmic:1603223, Cosmic:1609465, Cosmic:1998490, Cosmic:2009514, Cosmic:2036673, Cosmic:2164999, Cosmic:2301533, Cosmic:2318380, Cosmic:2361357, Cosmic:2668276, Cosmic-CLP:908123, DepMap:ACH-000849, DSMZ:ACC-738, DSMZCellDive:ACC-738, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:908123, GEO:GSE184543, GEO:GSM75169, GEO:GSM185095, GEO:GSM185096, GEO:GSM217591, GEO:GSM219929, GEO:GSM344356, GEO:GSM344406, GEO:GSM350502, GEO:GSM388214, GEO:GSM421880, GEO:GSM459714, GEO:GSM459722, GEO:GSM466357, GEO:GSM783955, GEO:GSM847418, GEO:GSM847497, GEO:GSM887301, GEO:GSM888376, GEO:GSM1008911, GEO:GSM1053727, GEO:GSM1172984, GEO:GSM1214565, GEO:GSM1238123, GEO:GSM1374663, GEO:GSM1374664, GEO:GSM1374665, GEO:GSM1401650, GEO:GSM1556177, GEO:GSM1556178, GEO:GSM1556179, GEO:GSM1556180, GEO:GSM1556181, GEO:GSM1661984, GEO:GSM1670087, GEO:GSM1833629, GEO:GSM2124671, GEO:GSM2258884, GEO:GSM2258885, GEO:GSM2258886, GEO:GSM2258887, GEO:GSM2258888, GEO:GSM2258889, GEO:GSM2258890, GEO:GSM2258891, GEO:GSM2258892, GEO:GSM2258893, GEO:GSM2258894, GEO:GSM2258895, GEO:GSM2258896, GEO:GSM2258897, GEO:GSM2258898, GEO:GSM2258899, GEO:GSM2258900, GEO:GSM2258901, GEO:GSM2258941, GEO:GSM2258942, GEO:GSM2258943, IARC_TP53:94, IBRC:C10095, ICLC:HTL99024, KCB:KCB 2011114YJ, LiGeA:CCLE_336, LINCS_HMS:50335, LINCS_LDP:LCL-1471, Lonza:809, NCBI_Iran:C208, NCI-DTP:MDA-MB-468, PharmacoDB:MDAMB468_907_2019, PRIDE:PXD001680, PRIDE:PXD005295, PRIDE:PXD008222, PRIDE:PXD022325, PRIDE:PXD030304, Progenetix:CVCL_0419, PubChem_Cell_line:CVCL_0419, SLKBase:3578, TOKU-E:2401, TOKU-E:3604, Ubigene:YC-D009, Wikidata:Q16880225

ID: CVCL_0419

Record Creation Time: 20220427T220756+0000

Record Last Update: 20260920T004444+0000

Ratings and Alerts

No rating or validation information has been found for MDA-MB-468.

No alerts have been found for MDA-MB-468.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 3971 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Du Y, et al. (2026) NUSAP1 Recruits DAXX to Suppress HIF-Driven Triple-Negative Breast Cancer Progression. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(5), e13380.

MacLean MR, et al. (2026) Selective inhibition of ALDH1A3 impedes breast cancer growth and metastasis by blocking ALDH1A3-driven transcriptional programs. iScience, 29(3), 114863.

Ohashi T, et al. (2026) ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancer research communications, 6(2), 421.

Zhang Y, et al. (2026) Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. eLife, 13.

Ochtrop P, et al. (2026) Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates. Nature communications, 17(1), 759.

Kano M, et al. (2026) Human epidermal growth factor receptor 3-targeted near-infrared photoimmunotherapy in a xenograft mouse model of breast cancer. BMC cancer, 26(1).

Guo X, et al. (2026) The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads. iScience, 29(7), 116390.

Hachey JS, et al. (2026) Exploring the 89Zr/177Lu Theranostic Pairing with an Extracellular Matrix-Targeted Radiopharmaceutical against Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(7), 1337.

Kopiasz RJ, et al. (2026) Modular Supramolecular Polycations Enable Efficient Delivery of Diverse RNA Therapeutics and Vaccines. Advanced materials (Deerfield Beach, Fla.),

38(16), e13315.

Umar SM, et al. (2026) ??-Catenin-Facilitated Glycolytic Reprogramming Fuels TNBC Progression: Therapeutic Blockade with XAV939. Technology in cancer research & treatment, 25, 15330338261425407.

Ranganathan S, et al. (2026) Gasdermin D Cleavage and Cytokine Release, Indicative of Pyroptotic Cell Death, Induced by Ophiobolin A in Breast Cancer Cell Lines. International journal of molecular sciences, 27(2).

Sun Y, et al. (2026) CircNSD2 promotes metastasis and immune escape by increasing the USP10/SRSF6-mediated alternative splicing of TPM1 in TNBC. Molecular cancer, 25(1).

Grafals-Ruiz N, et al. (2026) M6 metabolite contributes to the efficacy of the Rac/Cdc42 inhibitor MBQ-167 in metastatic breast cancer. Molecular cancer therapeutics.

Kumi J, et al. (2026) In Vitro Cytotoxicity Assessment of Leaves of Tieghemella heckelii on Breast (MDA-MB-468), Liver (HepG2), and Prostate (PC3) Cancer Cell Lines. BioMed research international, 2026(1), e2002140.

He G, et al. (2026) Vesicle trafficking 1 in breast cancer tissue and serum orchestrates metastatic progression and an immunosuppressive microenvironment. International immunopharmacology, 178, 116564.

Yao Y, et al. (2026) Identification and validation of a seven-gene metastasis-associated prognostic model in breast cancer. Frontiers in genetics, 17, 1770418.

Dang X, et al. (2026) Modular Assembly of Bioconjugates Enabled by a Pyridine-Based Chemoselective Sequential Conjugation Platform. Angewandte Chemie (International ed. in English), e3286230.

Rampa DR, et al. (2026) Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(8), 1454.

Gruber DR, et al. (2026) Targeted Delivery of a Potent STING Agonist Payload via an Antibody-Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models. Molecular cancer therapeutics, 25(3), 457.

Tikum AF, et al. (2026) [225Ac]Ac-labeled matuzumab is an effective radioimmunotherapeutic against EGFR-positive triple negative breast cancer. Breast cancer research : BCR, 28(1), 44.